EDAP TMS SA, the global leader in robotic energy-based therapies, will be featuring its leading robotic HIFU technology platform, Focal One, at the 41st World Congress of Endourology and Uro-Technology (WCET 2024) meeting. The event, taking place in Seoul, South Korea from August 12-16, 2024, serves as a forum for the advancement and dissemination of minimally- and non-invasive urologic surgical techniques.
EDAP’s Focal One platform has been generating strong interest from the global urology community, reflecting the increasing trend among urologists to utilize non-invasive HIFU technology for the management of prostate cancer. As part of its presence at WCET 2024, EDAP will provide hands-on Focal One simulations for urologists in attendance.
One of the highlights of the event will be a semi-live Focal One clinical procedure conducted by Dr. Tarik Benidir, Clinical Assistant Professor from the University of Florida. The presentation, titled ‘Focal One HIFU Ablation Treatment of Prostate Cancer’, will take place on Thursday, August 15th at 5:00 pm (KST).
The World Congress of Endourology and Uro-Technology meeting aims to provide evidence-based pathways for the management of a wide range of urologic diseases with a focus on minimally invasive treatments. The conference offers attendees an extensive amount of information on new and emerging minimally invasive treatments for various urologic conditions.
EDAP TMS is a recognized leader in the global therapeutic ultrasound market. The company develops, manufactures, promotes, and distributes minimally invasive medical devices for various pathologies using ultrasound technology. With its range of Robotic HIFU devices, including Focal One, and the addition of the ExactVu Micro-Ultrasound device, EDAP TMS offers a complete solution from diagnostics to focal treatment of Prostate Cancer.
For more information about EDAP TMS and its products, please visit the company’s website.